Related Experiment Video
Updated: Feb 16, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)
Arantza Azpilikueta1, Elixabet Bolaños1, Valerie Lang2
1Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigacion Sanitaria de Navarra (IdISNA), Pamplona, Spain.
Abstract:
TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A20 or CYLD downregulated CD137-elicited ubiquitination of TRAF2 and TAK1 upon stimulation with agonist monoclonal antibodies. Moreover, overexpression of A20 or CYLD downregulated CD137-induced NF-κB activation in cultured cells and in gene-transferred hepatocytes in vivo, while silencing these deubiquitinases enhanced CD137 costimulation of primary human CD8 T cells. Therefore A20 and CYLD directly downregulate the signaling from a T and NK-cell costimulatory receptor under exploitation for cancer immunotherapy in clinical trials.
Insights
Deubiquitinase enzymes A20 and CYLD regulate CD137 (4-1BB) signaling. These enzymes downregulate T-cell costimulation, impacting cancer immunotherapy strategies.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- CD137 (4-1BB) receptor stimulation activates NF-κB signaling via TRAF2-dependent K63-polyubiquitinations.
- Deubiquitinase enzymes (DUBs) are critical regulators of signaling pathways.
Purpose of the Study:
- To identify DUBs that regulate CD137-mediated signaling.
- To investigate the role of A20 and CYLD in CD137 signaling and NF-κB activation.
Main Methods:
- Coimmunoprecipitation assays to detect interactions between CD137, TRAF2, A20, and CYLD.
- Overexpression and silencing of A20 and CYLD in cell cultures and *in vivo* models.
- Assessment of TRAF2 and TAK1 ubiquitination levels.
- Measurement of NF-κB activation and CD8 T cell costimulation.
Main Results:
- A20 and CYLD were found to interact with CD137 and TRAF2 complexes.
- Overexpression of A20 or CYLD reduced CD137-induced ubiquitination of TRAF2 and TAK1.
- A20 and CYLD suppressed CD137-induced NF-κB activation *in vitro* and *in vivo*.
- Silencing A20 and CYLD enhanced CD137 costimulation of human CD8 T cells.
Conclusions:
- A20 and CYLD directly downregulate signaling from the CD137 costimulatory receptor.
- These findings have implications for optimizing CD137-based cancer immunotherapy.
More Related Videos
06:51Light-sheet Fluorescence Microscopy to Capture 4-Dimensional Images of the Effects of Modulating Shear Stress on the Developing Zebrafish Heart
Published on: August 10, 2018
11:31Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa
Published on: June 30, 2016
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Endocrine Signaling
Bacterial Signaling
Yeast Signaling
What is Cell Signaling?
Paracrine Signaling